Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nintedanib in Refractory Metastatic Colorectal Cancer (LUME-Colon 1)
NCT02149108Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Sep 2014
- Primary completion
- May 2016
- Countries
- 25
01
Overview
A Phase 3 trial of nintedanib in colorectal cancer (metastatic) (mCRC), sponsored by Boehringer Ingelheim. Started Sep 2014; status: completed.
02
Drugs
nintedanib
03
Conditions
colorectal cancer (metastatic) (mCRC)
Beyond the preview
Go deeper on NCT02149108.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02149108.